WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) has submitted the first portion of its application seeking U.S. approval of QTORIN rapamycin, a treatment for microcystic lymphatic malformations, moving the company closer to potentially commercializing the first approved therapy for the rare genetic disease.
The clinical-stage biotechnology company said it submitted the first module of a rolling New Drug Application to the U.S. Food and Drug Administration and expects to complete the filing during the second half of 2026.
The FDA’s rolling review process allows regulators to evaluate completed sections of an application before receiving the full submission, potentially shortening the review timeline.
If approved, QTORIN rapamycin could become the first FDA-approved treatment for microcystic lymphatic malformations, a progressive disorder affecting an estimated 30,000 people in the United States and characterized by malformed lymphatic vessels that can cause bleeding, infections and repeated hospitalizations.
The drug has received the FDA’s Breakthrough Therapy, Fast Track and Orphan Drug designations, as well as an FDA Orphan Products Development grant.
Chief Scientific Officer Jeff Martini said recent advances in molecular genetics have identified dysregulation of the PI3K/mTOR pathway as a key driver of the disease and that the company’s Phase 3 SELVA trial demonstrated statistically significant improvements across its primary and secondary endpoints.
As it advances the regulatory filing, Palvella is also preparing for a potential standalone U.S. launch in the first half of 2027, contingent on regulatory approval.
The company said it has expanded its commercial, medical affairs and patient services teams and launched an awareness campaign earlier this year aimed at improving recognition and diagnosis of the disease among physicians and patients.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.